Comparison · NCT01973036-82f784f8
Oxytocin vs Foley Catheter and Oxytocin: Number of Participants With Confirmed Histologic Chorioamnionitis/Funisitis
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Oxytocin vs Foley Catheter and Oxytocin: Number of Participants With Confirmed Histologic Chorioamnionitis/Funisitis. Trial comparisons, record NCT01973036-82f784f8. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01973036-82f784f8
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0833 | 0.0445 | 0.151 | wilson | |
| Risk in group 2 | 0.108 | 0.0595 | 0.187 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0242 | -0.112 | 0.0587 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.775 | 0.329 | 1.83 | log | |
| Odds ratio, group 1 over group 2 | 0.755 | 0.293 | 1.94 | log | |
| Number needed to treat, for one fewer participant with the outcome on Oxytocin than on Foley Catheter and Oxytocin | 41.3 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Oxytocin | This arm will receive oxytocin at a rate of 2 milliunits/milliliter. If the fetal status is reassuring, this can be increased by 2 milliunits/milliliter every 30 minutes to achieve an adequate contraction pattern as per the institution's definition to a maximum of 30 milliunits/milliliter. This infusion may be continued until delivery.~Oxytocin: Each arm will receive oxytocin at a rate of 2 milliunits/milliliter. If the fetal status is reassuring, this can be increased by 2 milliunits/milliliter every 30 minutes to achieve an adequate contraction pattern as per the institution's definition to a maximum of 30 milliunits/milliliter. This infusion may be continued until delivery. | 9 | 108 | OG000 |
| Group 2 | Foley Catheter and Oxytocin | Foley Catheter: A 30cc/16 French (16F) foley catheter will be inserted. Balloon will be inflated with 30 cc of sterile saline. The catheter will be taped to the patient's leg so that traction is maintained. The catheter will be assessed hourly for expulsion by a health care provider by applying gentle traction on the catheter or a vaginal examination if it is unclear by traction. Once the Foley catheter is expelled or 12 hours reached, the induction will be continued with oxytocin per this protocol.~Oxytocin: administered concurrently at a rate of 2 milliunits/milliliter. If the fetal status is reassuring, this can be increased by 2 milliunits/milliliter every 30 minutes to achieve an adequate contraction pattern as per the institution's definition to a maximum of 30 milliunits/milliliter. This infusion may be continued until delivery. | 10 | 93 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants With Confirmed Histologic Chorioamnionitis/Funisitis
- Description
- Chorioamnionitis/funisitis as determined by the pathologist examining the placenta
- Time frame
- Duration of hospital stay (average 3.4 days)
- Population
Source ClinicalTrials.gov
Trial
- Title
- FOLCROM Trial: Foley Catheter in Rupture of Membranes
- NCT number
- NCT01973036
- Phases
- NA
- Conditions
- Premature Rupture of Membranes
- Interventions
- Foley Catheter, Oxytocin
- Lead sponsor
- Geisinger Clinic
- Results first posted
- 2018-09-24
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01973036?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01973036-82f784f8